| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
Our newly found NF-κB inhibitor DHMEQ is very specific and ameliorates many disease models in animal experiments. However, it is hardly soluble to most solvents. Then, we have prepared more soluble DHMEQ analogs. We found that DHMEQ inhibited cellular invasion of ovarian carcinoma cells. As the new mechanism of inhibition, inhibition of the CXCL12/CXCR4 system with downstream proteases was suggested to be involved. In addition, DHMEQ increased the sensitivity of ovarian carcinoma cells to anticancer agents, and suppressed cachexia in ovarian cancer-bearing mice,.
|
